fbpx

Melbourne, Australia, and Utrecht, the Netherlands, April 24 2019 – The Baker Heart and Diabetes Institute, an independent Australian-based research institute recognized internationally for its groundbreaking work on the function of platelets in heart disease and cancer, has successfully installed their Milabs hybrid U-CT/OI small animal imager. This non-invasive imaging system combines 2D and 3D optical luminescence and fluorescence imaging with diagnostic X-ray CT. As such, the system enables the detection of fluorescence activated platelets in deep-seated organs or pathology – e.g., arterial and venous thrombosis, and difficult-to-treat cancer cells. Its unique 3D tomographic optical imaging capability is guided by high-resolution low-dose CT that can be used for complementary diagnostic applications such as angiography, atherosclerosis detection, and body fat composition analysis.

Baker Heart & Diabetes Institute invests in MILabs

Image courtesy of the Baker Heart & Diabetes Institute

According to Professor Karlheinz Peter, Deputy Director, Basic and Translational Science: “We are looking forward to using MILabs multimodal tomographic U-CT/OI imaging system to further extend our research in thrombotic and inflammatory diseases, such as myocardial infarction and atherosclerosis to autoimmune diseases, such as multiple sclerosis, and cancer.”

Professor Frederik Beekman, CEO/CSO of MILabs adds: “We are very gratified that Prof. Karlheinz Peter has selected our dual-modality OI/CT tomography system to support his groundbreaking research on the detection of activated platelets in the setting of heart disease, as well as his recently discovered novel approach to diagnosing, targeting and destroying difficult-to-treat cancer cells“

Trent Warburton, Managing Director at TrendBio Pty Ltd, MILabs’ exclusive Australian distributor, stated: “We are pleased that we can support the Baker Institute’s pioneering work with fluorescence tomography for assessing and monitoring plaque instability and thereby testing potential plaque-stabilizing drugs.”

About the Baker Heart and Diabetes Institute:

Commonly known as the Baker Institute, the institute is an Australian independent medical research institute headquartered in Melbourne, Victoria. Established in 1926, the institute is one of Australia’s oldest medical research organizations with a historical focus on cardiovascular disease. In 2008, it became the country’s first medical research institute to target diabetes, heart disease, obesity and their complications at the primary, clinical and population health levels. Most recently, the institute has extended its groundbreaking preclinical platelet research to targeting and destroying difficult-to-treat cancer cells. For more information, visit https://baker.edu.au/research

About MILabs B,V,:

MILabs has a history of providing a continuum of innovations to expand the applications of its multimodality imaging solutions used for the development of new diagnostic solutions and therapies. With its latest adaptive preclinical platform, MILabs has succeeded at commercializing a scalable imaging platform, able to accommodate PET, SPECT, Optical and CT imaging in a single integrated and user-friendly system.

Awarded the Commercial Innovation of the Year 2018 at the Molecular Imaging Congress, this platform is globally recognized for being able to deliver the highest quality molecular, functional and anatomical images.

For more information, visit: http://www.milabs.com or contact MILabs at [email protected]

About TrendBio Pty Ltd (Melbourne, Australia):

TrendBio a specialized instrument and consumable supplier servicing the Australian and New Zealand scientific markets. With products from market leaders across the divisions of Imaging, Genomics, Proteomics, Cell Biology, Biologics, and Chemistry. As a leading supplier, TrendBio provides high-level support covering technical, applications and sales. For more information, visit https://www.trendbio.com.au

Share on social media
Share on facebook
Share on twitter
Share on linkedin
Share on email

Spotlight on the Orthopedic Imaging at UMC Utrecht, the Netherlands – Prof. Harrie Weinans & Dr. Bart van der Wal

  – Spotlight on the Orthopedic Imaging at UMC Utrecht, the Netherlands –  – Prof. …

Read More →

Press Release: MILABS launches its 7th generation of preclinical imagers at the World Molecular Imaging Conference 2021

Under the new ownership of the Rigaku Group (Tokyo, Japan), MILabs is pushing the value …

Read More →

Press Release: RIGAKU Acquires Life Science Imaging Equipment Manufacturer MILabs

August 3, 2021 – Houten, the Netherlands Dear readers, We are very excited that MILabs …

Read More →

Press Release: Confocal PET Causes Spectral PET Breakthrough in Preclinical Imaging

Houten, the Netherlands – March 24, 2021 Using its unique Confocal PET technology, MILabs B.V …

Read More →

Spotlight on Akiva Mintz, MD, Ph.D. – Columbia University

Spotlight on Akiva Mintz, MD, Ph.D. – Columbia University – Bridging the “valley of death” …

Read More →

Spotlight on Bart Cornelissen, PhD – Department of Oncology, Oxford Institute for Radiation Oncology at University of Oxford

– Targeting Tumors from the inside –   Dr. Bart Cornelissen is Group Leader and …

Read More →

Spotlight on Prof. Twan Lammers – ExMI-RWTH Aachen

A Pioneering Mind in Nanomedicine and Theranostics Prof. Dr. Dr. Twan Lammers is Head of …

Read More →

Miltenyi Biotec strengthens its research capabilities for cell analysis and preclinical imaging by acquiring a MILabs’ premium Optical/CT imaging system

  Utrecht and Bergisch Gladbach, September 9, 2020 Miltenyi Biotec B.V. & Co. KG, a …

Read More →

MILabs announced the co-winners of the 2020 MILabs Image of the Year Award

September 4, 2020, Utrecht, The Netherlands Each year, at the occasion of the Annual Congress …

Read More →

Bayer AS installs top-of-the-line MILabs VECTor PET/SPECT/CT to advance its targeted alpha therapy programs

August 27, 2020, Oslo-Norway and Utrecht-The Netherlands Bayer AS has installed a state-of-the-art MILabs VECTor …

Read More →

Spotlight on Prof. Marion de Jong – Erasmus MC Rotterdam

Spotlight on Prof. Marion de Jong – Erasmus MC Rotterdam On the frontline of fighting …

Read More →

The University of Southampton enters the field of Correlative In-Vivo Imaging by Acquiring MILabs 3D/4D Optical/CT

May 12, 2020, Southampton, UK – Utrecht, the Netherlands The Faculty of Medicine, University of …

Read More →
Scroll to Top